Participated · Series B · Dec 2024

Veradermics is a late clinical-stage, dermatologist-founded biopharmaceutical company focused on first-in-class treatments for common dermatologic conditions. Its lead candidate, VDPHL01, is an extended-release, non-hormonal oral minoxidil tablet positioned to become the first FDA-approved oral therapy for pattern hair loss in both women and men. VDPHL01 is currently being evaluated in three Phase 3 trials after encouraging Phase 2 male data showed average hair count increases of 37.5 hairs/cm² at two months and 47.3 hairs/cm² at four months, with 90.5 % of participants reporting improved coverage and no serious adverse events. The formulation aims to sustain minoxidil exposure to follicles while avoiding cardiac risk–related concentration spikes seen in immediate-release versions. Proceeds from the recent financing will fund completion of Phase 3 registrational trials and a planned New Drug Application submission to the FDA. Beyond VDPHL01, Veradermics is building a pipeline of differentiated dermatology products that combine proven mechanisms with innovative delivery technologies to enhance efficacy, safety, and patient convenience.

Participated · Equity · Aug 2020

Pyramid Biosciences is developing targeted therapeutics that precisely modulate TRK family cell surface receptors. Its lead oncology candidate, PBI-200, is an orally active, highly brain-penetrant TRK inhibitor designed to overcome acquired resistance mutations seen with current TRK therapies and to treat genomically-defined solid tumors including primary and metastatic brain cancers. PBI-100 is a first-in-class selective TRK modulator with anti-itch, anti-inflammatory and antiproliferative effects being developed for dermatological and inflammatory diseases such as psoriasis and atopic dermatitis. The company intends to advance both programs clinically and expand its scientific development and business strategy. Pyramid is based in Waltham, Mass. The company recently closed $28 million in funding to accelerate these clinical programs.